Sopharma AD (3JR) Stock Overview

Produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. More details

3JR fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	5/6
Financial Health	5/6
Dividends	2/6

Rewards

Price-To-Earnings ratio (12.6x) is below the German market (16.9x)

Earnings grew by 81.5% over the past year

Risk Analysis

Volatile share price over the past 3 months compared to the German market

3JR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Sopharma AD Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sopharma AD
Historical stock prices
Current Share Price	€1.85
52 Week High	€2.48
52 Week Low	€1.50
Beta	0.10
1 Month Change	3.35%
3 Month Change	19.35%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	177.50%

Recent updates

Shareholder Returns

	3JR	DE Pharmaceuticals	DE Market
7D	-0.5%	16.1%	-0.8%
1Y	n/a	47.4%	2.2%

Return vs Industry: Insufficient data to determine how 3JR performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 3JR performed against the German Market.

Price Volatility

Is 3JR's price volatile compared to industry and market?
3JR volatility
3JR Average Weekly Movement	10.1%
Pharmaceuticals Industry Average Movement	5.9%
Market Average Movement	5.7%
10% most volatile stocks in DE Market	13.2%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: 3JR's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 3JR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1933	6,005	Ognian Donev	www.sopharmagroup.com

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana, a herbal medicine to reduce the stress; veterinary vaccines; and medical devices, such as gauzes, compresses, and dressing. The company also provides food supplements; medicinal and cosmetic products, including plasters, bandages, herbal cosmetics, and sanitary-hygiene products; and yophilic products, ointments, syrups, drops, suppositories, inhalers, haemodialysis concentrates, sachets, substances, infusion solutions, veterinary vaccines, solutions and chemical substances and mixture.

Sopharma AD Fundamentals Summary

How do Sopharma AD's earnings and revenue compare to its market cap?
3JR fundamental statistics
Market cap	€1.02b
Earnings (TTM)	€80.63m
Revenue (TTM)	€1.40b

12.6x

P/E Ratio

0.7x

P/S Ratio

Is 3JR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3JR income statement (TTM)
Revenue	€1.40b
Cost of Revenue	€1.06b
Gross Profit	€341.26m
Other Expenses	€260.63m
Earnings	€80.63m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Jul 30, 2026

Earnings per share (EPS)	0.15
Gross Margin	24.41%
Net Profit Margin	5.77%
Debt/Equity Ratio	43.9%

How did 3JR perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

26%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/25 15:32
End of Day Share Price	2026/06/25 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sopharma AD is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Sopharma ADDB:3JR Stock Report